Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..
Krystal Biotech has raised $160.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2023.
Krystal Biotech's investors include Redmile Group, Frazier Life Sciences, Frazier Healthcare Partners, Avoro Capital Advisors, Sun Pharmaceutical.
Krystal Biotech is headquartered in Pittsburgh, United States.
Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..
Krystal Biotech is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Krystal Biotech — Funding & Investors." VCBacked, May 21, 2023, https://www.vcbacked.co/company/krystal-biotech. Accessed August 14, 2026.
VCBacked. (2023). Krystal Biotech — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/krystal-biotech
{{cite web |title=Krystal Biotech — Funding & Investors |url=https://www.vcbacked.co/company/krystal-biotech |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated